ホームページ GPCR & G Protein GLP-1 Receptor

GLP-1 Receptor

GLP-1 Receptor製品

  • All (17)
  • GLP-1 Receptor阻害剤 (1)
  • GLP-1 Receptor作動薬(8)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S8256 Liraglutide Liraglutideは、長時間作用型グルカゴン様ペプチド-1(GLP-1)受容体作動薬です。
Frontiers in Endocrinology, June 25, 2024, 1395028
bioRxiv, December 17, 2024, nan
Diabetes, December 1, 2025, 2375-2389
S9851 Danuglipron (PF-06882961) 非ペプチド作動薬であるDanuglipron (PF-06882961) は、Trp33ECDを有するグルカゴン様ペプチド-1（GLP-1）受容体のみにおいてカノニカルGタンパク質シグナル伝達活性を活性化します。
bioRxiv, 2024, nan
P1237New Survodutide Survodutide (BI 456906) is a potent, selective GCGR/GLP‑1R dual agonist with an EC50 of 0.52 nM and 0.33 nM in CHO‑K1 cells, respectively. It exerts robust anti‑obesity efficacy by increasing energy expenditure and decreasing food intake.
P1273New Ecnoglutide（XW003） Ecnoglutide (XW003) is a long‑acting, cAMP‑biased agonist of the glucagon‑like peptide‑1 (GLP‑1) receptor that selectively enhances cAMP signaling over β‑arrestin recruitment, and exhibits potential for the treatment of type 2 diabetes and obesity.
E1827 AZD5004 (ECC5004) ECC5004(AZD5004, GLP-1 agonist (Eccogene))は、消化器系疾患、内分泌・代謝性疾患の治療に用いられる低分子GLP-1受容体作動薬（GLP-1RA）です。ECC5004は、肥満、2型糖尿病、代謝機能関連脂肪性肝炎（MASH）の治療に用いられる可能性があります。
P1278New Brenipatide Brenipatide (LY-3537031) is a dual GLP-1/GIP receptor agonist with the potential to be used in addiction and psychiatric indications, alongside standard metabolic/obesity studies.
P1230 Retatrutide (LY3437943) Retatrutide (LY3437943)は、グルカゴン受容体（GCGR）、グルカゴン様ペプチド-1受容体（GLP-1R）、およびグルコース依存性インスリン分泌刺激ポリペプチド受容体（GIPR）のトリプルアゴニストペプチドとして作用します。RetatrutideはヒトGCGR、GLP-1R、GIPRに、それぞれEC50値5.79、0.775 nM、0.0643で結合します。Retatrutideは肥満に関する研究での利用の可能性があります。
E6682New CT-996(RO7795081，RG6652） CT‑996 (RO7795081, RG6652) is an orally active, cAMP‑biased agonist of GLP‑1R with an EC50 ≈ 0.049 nM for cAMP, with minimal β‑arrestin recruitment and receptor internalization, suitable for research on type 2 diabetes and obesity.
P1274New Ribupatide HRS9531 (ribupatide) is an oral dual GLP‑1/GIP receptor agonist that demonstrates potent glycemic control and clinically meaningful weight‑loss efficacy in obesity and type 2 diabetes trials.
S8256 Liraglutide Liraglutideは、長時間作用型グルカゴン様ペプチド-1(GLP-1)受容体作動薬です。
Frontiers in Endocrinology, June 25, 2024, 1395028
bioRxiv, December 17, 2024, nan
Diabetes, December 1, 2025, 2375-2389
S9851 Danuglipron (PF-06882961) 非ペプチド作動薬であるDanuglipron (PF-06882961) は、Trp33ECDを有するグルカゴン様ペプチド-1（GLP-1）受容体のみにおいてカノニカルGタンパク質シグナル伝達活性を活性化します。
bioRxiv, 2024, nan
P1237New Survodutide Survodutide (BI 456906) is a potent, selective GCGR/GLP‑1R dual agonist with an EC50 of 0.52 nM and 0.33 nM in CHO‑K1 cells, respectively. It exerts robust anti‑obesity efficacy by increasing energy expenditure and decreasing food intake.
P1273New Ecnoglutide（XW003） Ecnoglutide (XW003) is a long‑acting, cAMP‑biased agonist of the glucagon‑like peptide‑1 (GLP‑1) receptor that selectively enhances cAMP signaling over β‑arrestin recruitment, and exhibits potential for the treatment of type 2 diabetes and obesity.
E1827 AZD5004 (ECC5004) ECC5004(AZD5004, GLP-1 agonist (Eccogene))は、消化器系疾患、内分泌・代謝性疾患の治療に用いられる低分子GLP-1受容体作動薬（GLP-1RA）です。ECC5004は、肥満、2型糖尿病、代謝機能関連脂肪性肝炎（MASH）の治療に用いられる可能性があります。
P1278New Brenipatide Brenipatide (LY-3537031) is a dual GLP-1/GIP receptor agonist with the potential to be used in addiction and psychiatric indications, alongside standard metabolic/obesity studies.
P1230 Retatrutide (LY3437943) Retatrutide (LY3437943)は、グルカゴン受容体（GCGR）、グルカゴン様ペプチド-1受容体（GLP-1R）、およびグルコース依存性インスリン分泌刺激ポリペプチド受容体（GIPR）のトリプルアゴニストペプチドとして作用します。RetatrutideはヒトGCGR、GLP-1R、GIPRに、それぞれEC50値5.79、0.775 nM、0.0643で結合します。Retatrutideは肥満に関する研究での利用の可能性があります。
E6682New CT-996(RO7795081，RG6652） CT‑996 (RO7795081, RG6652) is an orally active, cAMP‑biased agonist of GLP‑1R with an EC50 ≈ 0.049 nM for cAMP, with minimal β‑arrestin recruitment and receptor internalization, suitable for research on type 2 diabetes and obesity.
P1274New Ribupatide HRS9531 (ribupatide) is an oral dual GLP‑1/GIP receptor agonist that demonstrates potent glycemic control and clinically meaningful weight‑loss efficacy in obesity and type 2 diabetes trials.
S8256 Liraglutide Liraglutideは、長時間作用型グルカゴン様ペプチド-1(GLP-1)受容体作動薬です。
Frontiers in Endocrinology, June 25, 2024, 1395028
bioRxiv, December 17, 2024, nan
Diabetes, December 1, 2025, 2375-2389
S9851 Danuglipron (PF-06882961) 非ペプチド作動薬であるDanuglipron (PF-06882961) は、Trp33ECDを有するグルカゴン様ペプチド-1（GLP-1）受容体のみにおいてカノニカルGタンパク質シグナル伝達活性を活性化します。
bioRxiv, 2024, nan
P1237New Survodutide Survodutide (BI 456906) is a potent, selective GCGR/GLP‑1R dual agonist with an EC50 of 0.52 nM and 0.33 nM in CHO‑K1 cells, respectively. It exerts robust anti‑obesity efficacy by increasing energy expenditure and decreasing food intake.
P1273New Ecnoglutide（XW003） Ecnoglutide (XW003) is a long‑acting, cAMP‑biased agonist of the glucagon‑like peptide‑1 (GLP‑1) receptor that selectively enhances cAMP signaling over β‑arrestin recruitment, and exhibits potential for the treatment of type 2 diabetes and obesity.
E1827 AZD5004 (ECC5004) ECC5004(AZD5004, GLP-1 agonist (Eccogene))は、消化器系疾患、内分泌・代謝性疾患の治療に用いられる低分子GLP-1受容体作動薬（GLP-1RA）です。ECC5004は、肥満、2型糖尿病、代謝機能関連脂肪性肝炎（MASH）の治療に用いられる可能性があります。
P1278New Brenipatide Brenipatide (LY-3537031) is a dual GLP-1/GIP receptor agonist with the potential to be used in addiction and psychiatric indications, alongside standard metabolic/obesity studies.
P1230 Retatrutide (LY3437943) Retatrutide (LY3437943)は、グルカゴン受容体（GCGR）、グルカゴン様ペプチド-1受容体（GLP-1R）、およびグルコース依存性インスリン分泌刺激ポリペプチド受容体（GIPR）のトリプルアゴニストペプチドとして作用します。RetatrutideはヒトGCGR、GLP-1R、GIPRに、それぞれEC50値5.79、0.775 nM、0.0643で結合します。Retatrutideは肥満に関する研究での利用の可能性があります。
E6682New CT-996(RO7795081，RG6652） CT‑996 (RO7795081, RG6652) is an orally active, cAMP‑biased agonist of GLP‑1R with an EC50 ≈ 0.049 nM for cAMP, with minimal β‑arrestin recruitment and receptor internalization, suitable for research on type 2 diabetes and obesity.
P1237New Survodutide Survodutide (BI 456906) is a potent, selective GCGR/GLP‑1R dual agonist with an EC50 of 0.52 nM and 0.33 nM in CHO‑K1 cells, respectively. It exerts robust anti‑obesity efficacy by increasing energy expenditure and decreasing food intake.
P1273New Ecnoglutide（XW003） Ecnoglutide (XW003) is a long‑acting, cAMP‑biased agonist of the glucagon‑like peptide‑1 (GLP‑1) receptor that selectively enhances cAMP signaling over β‑arrestin recruitment, and exhibits potential for the treatment of type 2 diabetes and obesity.
P1278New Brenipatide Brenipatide (LY-3537031) is a dual GLP-1/GIP receptor agonist with the potential to be used in addiction and psychiatric indications, alongside standard metabolic/obesity studies.
E6682New CT-996(RO7795081，RG6652） CT‑996 (RO7795081, RG6652) is an orally active, cAMP‑biased agonist of GLP‑1R with an EC50 ≈ 0.049 nM for cAMP, with minimal β‑arrestin recruitment and receptor internalization, suitable for research on type 2 diabetes and obesity.
P1274New Ribupatide HRS9531 (ribupatide) is an oral dual GLP‑1/GIP receptor agonist that demonstrates potent glycemic control and clinically meaningful weight‑loss efficacy in obesity and type 2 diabetes trials.
P1237New Survodutide Survodutide (BI 456906) is a potent, selective GCGR/GLP‑1R dual agonist with an EC50 of 0.52 nM and 0.33 nM in CHO‑K1 cells, respectively. It exerts robust anti‑obesity efficacy by increasing energy expenditure and decreasing food intake.
P1273New Ecnoglutide（XW003） Ecnoglutide (XW003) is a long‑acting, cAMP‑biased agonist of the glucagon‑like peptide‑1 (GLP‑1) receptor that selectively enhances cAMP signaling over β‑arrestin recruitment, and exhibits potential for the treatment of type 2 diabetes and obesity.
P1278New Brenipatide Brenipatide (LY-3537031) is a dual GLP-1/GIP receptor agonist with the potential to be used in addiction and psychiatric indications, alongside standard metabolic/obesity studies.
E6682New CT-996(RO7795081，RG6652） CT‑996 (RO7795081, RG6652) is an orally active, cAMP‑biased agonist of GLP‑1R with an EC50 ≈ 0.049 nM for cAMP, with minimal β‑arrestin recruitment and receptor internalization, suitable for research on type 2 diabetes and obesity.